- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07951606
Safty and Efficacy of KH658 in Subjects With Diabetic Retinopathy
A Phase II Study to Evaluate the Safty and Efficacy of KH658 Gene Therapy in Participants With Diabetic Retinopathy (DR)
KH658 is a adeno-associated virus (AAV) vector-based gene therapy for suprachoroidal space injection. The long-term, stable therapeutic protein after one time injection for DR could potentially reduce the treatment burden and maintain visual acuity and retinal anatomical stability
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 2
Kontakter og lokationer
Studiekontakt
- Navn: Yan Cheng
- Telefonnummer: 86-028-81258178
- E-mail: 025171@cnkh.com
Studiesteder
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Kina, 100730
- Peking Union Medical College Hospital
-
Kontakt:
- Youxin Chen, MD
-
-
Sichuan
-
Chengdu, Sichuan, Kina, 610041
- West China Hospital of Sichuan University
-
Kontakt:
- Fang Lu, MD
- Telefonnummer: 028-85422114
- E-mail: scudag@scu.edu.cn
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Are willing and able to sign the informed consent form (ICF);
- Male or female ≥ 18 to 85 years of age with DR secondary to diabetes mellitus Type 1 or Type 2;
- Moderately Severe NPDR or Severe NPDR (DRSS levels 47-53);
- Have a ETDRS BCVA letter score of ≥ 69 (approximately 20/40 Snellen equivalent) in the study eye at Screening;
- Have a ETDRS BCVA letter score of ≥19 (approximately 20/400 Snellen equivalent) in the fellow eye at Screening;
- No active CI-DME
Exclusion Criteria:
- Have any non-DR disease in the study eye judged by the investigator that could impact macular examination or affect central vision or visual acuity improvement (such as macular hemorrhage, central retinal vein occlusion, fovea scar, fibrosis or atrophy etc.);
- Have any vitreous hemorrhage or history of vitreous hemorrhage in the study eye;
- Presence of an implant (excluding intraocular lens), opacification of the refractive medium or miosis that affects fundus examination;
- Have a history of or presence of retinal detachment or choroidal detachment in the study eye.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Enkelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: KH658 Dose 1
In-office delivers KH658 to the suprachoroidal space |
KH658 Dose 1 suprachoriodal single injection |
|
Eksperimentel: KH658 Dose 2
In-office delivers KH658 to the suprachoroidal space |
KH658 Dose 2 suprachoriodal single injection |
|
Aktiv komparator: Ranibizumab
Ranibizumab IVT Injection |
Administered by intravitreal injection once a month |
|
Ingen indgriben: Observational Control
Observational Control |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Proportion of Participants with a ≥2 steps DRSS Improvement From Baseline in Diabetic Retinopthy
Tidsramme: At Week 52
|
To evaluate the efficacy of KH658 ophthalmic injection in patients with DR, assessed by the proportion of participants achieving a ≥2 steps improvement on the DRSS from baseline. |
At Week 52
|
|
Proportion of Participants Developing Vision-Threatening Events (VTEs)
Tidsramme: At Week 52
|
To evaluate the efficacy of KH658 ophthalmic injection in patients with DR, assessed by the proportion of participants developing VTEs. VTEs include vision-threatening complications (VTCs) and center-involved diabetic macular edema (CI-DME) requiring rescue treatment. |
At Week 52
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Proportion of Participants With Improvement, Maintanance, or Worsening in DRSS Score From Baseline
Tidsramme: At Week 24, Week 52
|
To evaluate the efficacy of KH658 ophthalmic injection in patients with DR, assessed by the proportion of participants demonstrating improvement, maintance, or worsening in the DRSS score compared to baseline. |
At Week 24, Week 52
|
|
Time to first occurrence of VTEs
Tidsramme: Day 1 to Week 52
|
To evaluate the efficacy of KH658 ophthalmic injection in patients with DR, assessed by the time to first occurrence of VTEs. |
Day 1 to Week 52
|
|
Incidence of adverse events (AEs) and serious adverse events (SAEs)
Tidsramme: Through Week 52
|
To evaluate the safty of KH658 ophthalmic injection in patients with DR, assessed by the incidence of AEs and SAEs |
Through Week 52
|
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of rescue treatments
Tidsramme: At Week 24, Week 52
|
To evaluate the efficacy of KH658 ophthalmic injection in patients with DR, assessed by the number of rescue treatments |
At Week 24, Week 52
|
Samarbejdspartnere og efterforskere
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Sygdomme i det endokrine system
- Karsygdomme
- Hjerte-kar-sygdomme
- Diabetes mellitus
- Øjensygdomme
- Diabetiske angiopatier
- Diabetes komplikationer
- Nethindesygdomme
- Diabetisk retinopati
- Aminosyrer, peptider og proteiner
- Proteiner
- Antistoffer, monoklonal, humaniseret
- Antistoffer, monoklonal
- Antistoffer
- Immunoglobuliner
- Immunoproteiner
- Blodproteiner
- Serum globuliner
- Globuliner
- Ranibizumab
Andre undersøgelses-id-numre
- KH658-40301
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .